Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KATY REZVANI and ELIZABETH SHPALL.
KATY REZVANI
Connection Strength
4.310
ELIZABETH SHPALL
  1. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol Ther. 2017 08 02; 25(8):1769-1781.
    View in: PubMed
    Score: 0.600
  2. CAR-Transduced Natural Killer Cells. Reply. N Engl J Med. 2020 05 07; 382(19):1866-1867.
    View in: PubMed
    Score: 0.183
  3. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2018 04; 32(4):960-970.
    View in: PubMed
    Score: 0.153
  4. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531.
    View in: PubMed
    Score: 0.151
  5. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.147
  6. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant. 2016 05; 16(5):1492-502.
    View in: PubMed
    Score: 0.137
  7. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.134
  8. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant. 2015 Jun; 50 Suppl 2:S55-62.
    View in: PubMed
    Score: 0.130
  9. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.128
  10. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6.
    View in: PubMed
    Score: 0.125
  11. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014 Dec; 3(12):1435-43.
    View in: PubMed
    Score: 0.125
  12. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S18-22.
    View in: PubMed
    Score: 0.123
  13. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.
    View in: PubMed
    Score: 0.122
  14. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. 2014 Aug; 16(8):1153-7.
    View in: PubMed
    Score: 0.119
  15. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014 May; 99(5):836-47.
    View in: PubMed
    Score: 0.118
  16. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e105-9.
    View in: PubMed
    Score: 0.118
  17. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
    View in: PubMed
    Score: 0.116
  18. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
    View in: PubMed
    Score: 0.116
  19. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.116
  20. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013 Jul 11; 122(2):227-38.
    View in: PubMed
    Score: 0.113
  21. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.
    View in: PubMed
    Score: 0.056
  22. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol. 2021; 11:800110.
    View in: PubMed
    Score: 0.051
  23. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis. 2021 10 20; 73(8):1346-1354.
    View in: PubMed
    Score: 0.051
  24. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol. 2021 09 01; 96(9):E350-E353.
    View in: PubMed
    Score: 0.049
  25. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.048
  26. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605.
    View in: PubMed
    Score: 0.048
  27. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.
    View in: PubMed
    Score: 0.048
  28. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 08 17; 22(8):1214-1225.
    View in: PubMed
    Score: 0.047
  29. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.046
  30. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.
    View in: PubMed
    Score: 0.045
  31. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
    View in: PubMed
    Score: 0.045
  32. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
    View in: PubMed
    Score: 0.045
  33. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.
    View in: PubMed
    Score: 0.045
  34. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2019 02 23; 219(6):898-907.
    View in: PubMed
    Score: 0.042
  35. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.039
  36. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340.
    View in: PubMed
    Score: 0.039
  37. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.
    View in: PubMed
    Score: 0.039
  38. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.039
  39. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.
    View in: PubMed
    Score: 0.038
  40. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366.
    View in: PubMed
    Score: 0.037
  41. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670.
    View in: PubMed
    Score: 0.037
  42. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017 03 09; 2(5):e89530.
    View in: PubMed
    Score: 0.037
  43. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117.
    View in: PubMed
    Score: 0.035
  44. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
    View in: PubMed
    Score: 0.035
  45. Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. J Mol Diagn. 2016 09; 18(5):638-642.
    View in: PubMed
    Score: 0.035
  46. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016 07 15; 122(14):2186-96.
    View in: PubMed
    Score: 0.035
  47. Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2016 Jun 01; 213(11):1701-7.
    View in: PubMed
    Score: 0.034
  48. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.
    View in: PubMed
    Score: 0.031
  49. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014 Jun; 49(6):793-9.
    View in: PubMed
    Score: 0.030
  50. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.